Document is current
Any future updates will be listed below
-
Authors
Aramayo-Singelmann, Carmen
Halimeh, Susan
Proske, Pia
Vignalingarajah, Abinuja
Cario, Holger
Christensen, Morten O.
Yamamoto, Raina
Röth, Alexander https://orcid.org/0000-0003-4414-7699
Reinhardt, Dirk
Reinhardt, Hans Christian https://orcid.org/0000-0001-5706-9349
Alashkar, Ferras https://orcid.org/0000-0001-7530-8892
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (DFG; grant FU356/12-1)
Universitätsklinikum Essen
- License Information
-
More Information
Article History
Received: 21 February 2022
Accepted: 12 May 2022
First Online: 13 June 2022
Competing interests
: Carmen Aramayo-Singelmann received honorarium for participation in advisory boards from Novartis and Global Blood Therapeutics. Susan Halimeh received a speaker honorarium from Bayer HealthCare GmbH, CSL Behring GmbH, Novo Nordisk Pharma GmbH, Octapharma GmbH, Swedish Orphan Biovitrum, Roche Pharma GmbH, received honorarium for participation in advisory boards from Novo Nordisk Pharma GmbH and Vhugai Pharma, and received a research grant from Swedish Orphan Biovitrum. Dirk Reinhardt received honorarium for participation in advisory boards from Bristol Myers Squibb and Hexal AG and funding from bluebird bio: KIKHÄMOCare and CSL Behring GmbH: research grant. Ferras Alashkar received honorarium for participation in advisory boards from Novartis, bluebird bio, Global Blood Therapeutics and Bristol Myers Squibb, received a speaker honorarium from Novartis, bluebird bio, Global Blood Therapeutics and received a honorarium from Novartis, Bristol Myers Squibb and Global Blood Therapeutics for consultancy. Pia Proske, Abinuja Vignalingarajah, Holger Cario, Morten O. Christensen, Raina Yamamoto, Alexander Röth, and Hans Christian Reinhardt declare that they have no financial disclosures.
